Exosome Analytics is a quickly growing Company with very high technical expertise in exosome research and liquid biopsy tests. Company has developed brand new solutions for highly sensitive analysis of histological markers on exosomes. Based on these techniques, very promising results for early screening and profiling of ovarian and prostate tumors were obtained and now needs to commercialize the first products, organize clinical trials to evaluate exosome-based platform for for early screening of urogenital cancers
Several patents are being finalized, and a number of prospective clients are already interested in the scalable RUO products. In parallel, the preclinical study of exosome-based early cancer diagnostic platform is ongoing. Collaboration with public and private companies is established
Exosome Analytics is supported by Genopole incubator and accelerator WILCO.
The market :
The expected market growth of exosome-related technologies and liquid biopsy over the next 5-10y is huge ( The size is expected to reach 660 M€ for exosome research market and 7B€ for liquid biopsy market). Currently, very few competitors are present on the market. The market essentially depends on the development of new technologies and to date there are very few products (if any) allowing the detection of histological markers on pathological exosomes.
The Company was founded by head scientist (Master in physics, PhD in molecular biology with 20+ years experience in fundamental science and technological development: Ecole Normale Supérieure de Paris, Max Planck Institute, Argonne National Laboratory and others).
Financial activity of the company is assured by an expert in fundraising.
The Scientific Council is made up of experts in exosome research and oncologist
Missions/ Areas of Responsibility:
•Responsibility for Business development and operational activity of the company
Short term priorities: Launching the RUO products (commercialization, regulatory filings, participation in clients acquisition, etc)
Long term priorities: Clinical validation of diagnostic platforms for early screening of ovarian and prostate cancers (Medical Device Clinical Trials) for FDA/EMA certification
Offer: The terms of participation will depend on qualification and experience of the candidate as well as the volume of investment and time devoted to the development of the company
- You are a qualified and enthusiastic person ready to invest your time and knowledge in the operational development of the startup
-You have a credible experience within a medtech or biotech start-up (operations/business development) or within a commercial department of a healthcare company.
-You are very familiar with the healthcare business ecosystem (overall value chain, from R&D and labs to final patient & investors)
-You have a solid knowledge of the certification process and of the French and European biomedical market. - A double competence (commercial / scientific) would be appreciated, but not mandatory.